IMMUNIC INC (IMUX) Stock News

USA - NASDAQ:IMUX - US4525EP1011 - Common Stock

0.8314 USD

-0.01 (-1.02%)

Last: 10/21/2025, 2:48:51 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMUX Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Immunic, Inc.

Immunic to Participate in Scientific and Investor Conferences in October

22 days ago - By: Benzinga - Mentions: EA MLTX ANRO

This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

22 days ago - By: Benzinga - Mentions: VSEC RVPH GBFH ANRO

This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

a month ago - By: Immunic, Inc.

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

a month ago - By: Immunic, Inc.

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

3 months ago - By: The Motley Fool

Immunic (IMUX) Q2 Loss Widens 25%

4 months ago - By: Stocktwits

Immunic to Participate in Scientific and Industry Conferences in May

4 months ago - By: Stocktwits

Immunic, Inc. Announces Proposed Public Offering

2 months ago - By: Immunic, Inc.

Immunic to Participate in Investor and Scientific Conferences in September

3 months ago - By: Immunic, Inc.

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Stocktwits

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

4 months ago - By: Stocktwits

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

4 months ago - By: Stocktwits - Mentions: UBS

Immunic to Participate in Investor, Scientific and Industry Conferences in June

4 months ago - By: Stocktwits - Mentions: IMU

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

4 months ago - By: Stocktwits

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

5 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Proposed Public Offering

4 months ago - By: Stocktwits

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

4 months ago - By: Immunic, Inc.

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

5 months ago - By: Immunic, Inc.

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

5 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

5 months ago - By: Immunic, Inc.

Immunic to Participate in Investor, Scientific and Industry Conferences in June

5 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

6 months ago - By: Immunic, Inc.

Immunic to Participate in Scientific and Industry Conferences in May

6 months ago - By: Immunic, Inc.

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

6 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

7 months ago - By: Stocktwits - Mentions: VTI VXF

Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode

7 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

7 months ago - By: Immunic, Inc.

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

8 months ago - By: Immunic, Inc.

Immunic to Participate in Scientific and Investor Conferences in March

8 months ago - By: Immunic, Inc.

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

8 months ago - By: Immunic, Inc.

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

9 months ago - By: Immunic, Inc.

Immunic to Participate in Investor and Scientific Conferences in February